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ABSTRACT
Aims To (1) estimate the number of Parties to the Framework Convention on Tobacco Control (FCTC) providing tobacco
dependence treatment in accordance with the recommendations of Article 14 and its guidelines; (2) assess association
between provision and countries’ income level; and (3) assess progress over time. Design Cross-sectional study.
Setting Online survey from December 2014 to July 2015. Participants Contacts in 172 countries were surveyed,
representing 169 of the 180 FCTC Parties at the time of the survey. Measurements A 26-item questionnaire based
on the Article 14 recommendations including tobacco treatment infrastructure and cessation support systems. Progress
over time was assessed for those countries that also participated in our 2012 survey and did not change country income
level classiﬁcation. Findings We received responses from contacts in 142 countries, an 83% response rate. Overall, 54%
of respondents reported that their country had an ofﬁcially identiﬁed person responsible for tobacco dependence treatment,
32% an ofﬁcial national treatment strategy, 40% ofﬁcial national treatment guidelines, 25% a clearly identiﬁed budget for
treatment, 17% text messaging, 23% free national quitlines and 26% specialized treatment services. Most measures were
associated positively and signiﬁcantly with countries’ income level (P< 0.001). Measures not associated signiﬁcantly with
income level included mandatory recording of tobacco use (30% of countries), offering help to health-care workers (HCW)
to stop using tobacco (44%), brief advice integrated into existing services (44%), and training HCW to give brief advice
(81%). Reporting having an ofﬁcially identiﬁed person responsible for tobacco cessation was the only measure with a sta-
tistically signiﬁcant improvement over time (P = 0.0351). Conclusion Fewer than half of countries that are Parties to
the Framework Convention on Tobacco Control have implemented the recommendations of Article 14 and its guidelines,
and for most measures, provision was greater the higher the country’s income. There was little improvement in treatment
provision between 2012 and 2015 in all countries.
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INTRODUCTION
Article 14 of the World Health Organization (WHO)
Framework Convention on Tobacco Control (FCTC)
requires Parties to promote tobacco cessation and imple-
ment effective measures to help tobacco users quit [1].
The Article 14 guidelines, adopted at the fourth
Conference of the Parties in 2010 [2] provide further
details on the implementation of Article 14 [3], including
the key elements of basic treatment infrastructure and
support systems that Parties should implement, and were
outlined in our previous paper [4].
Our previous survey found that most countries, espe-
cially middle- and low-income countries, had not fully
implemented the Article 14 guidelines recommendations
[4]. The aims of this study were to (1) estimate the cur-
rent level of provision of tobacco dependence treatment;
(2) assess association between provision and countries’
income level; and (3) assess progress since the previous
survey.
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METHODS
We identiﬁed contacts in 169 FCTC Parties at the time of
the survey. We excluded the EU as a non-state Party and
were unable to ﬁnd contacts for 10 Parties. Our survey
sample consisted of 168 Parties and the United Kingdom
(which is one Party but made up of four countries
(England, Northern Ireland, Scotland and Wales), each
with a different health-care system, which were therefore
surveyed individually)—172 countries in all.
We approached the contacts from our previous survey
by e-mail in December 2014, inviting them to take part
in this survey. For contacts we could not reach or who
did not reply, we identiﬁed new ones with the help of the
WHO regional ofﬁces, the Framework Convention Alliance
(FCA), Action on Smoking and Health (ASH) in the United
States, the InterAmerican Heart Foundation and other
professional networks and contacts. The contacts included
tobacco treatment specialists and government and non-
government representatives, involved in tobacco cessation
or tobacco control in their countries.
The questionnaire was based on our previous one,
with a few questions improved for clarity or for better
alignment with the Article 14 guidelines. However, this
time we conducted two surveys: one on treatment pro-
vision and one on treatment guidelines. In this paper
we report the ﬁndings of the treatment provision
survey only. The guidelines results are reported in a
second paper. The questionnaire was translated into
French, Spanish and Russian and sent electronically
as a Word attachment. A link to an online version of
the questionnaire in English was also provided. The
treatment questionnaire (see Appendix S1) covered
basic treatment infrastructure (an ofﬁcially identiﬁed
person in government responsible for cessation, a na-
tional treatment strategy, a treatment budget, treat-
ment guidelines, mandatory recording of tobacco use
in medical notes, training of health-care workers
(HCW) to give brief advice and help to stop using to-
bacco) and cessation support systems (brief advice inte-
grated into existing services, medications, mass media
campaigns, quitlines, text messaging, specialized treat-
ment services). In order to help validate the responses,
we asked the respondents to send supporting informa-
tion and references with their answers where possible.
We sent reminders every 2 weeks until July 2015,
when the survey was closed.
Survey data were analysed by country World Bank
(WB) income level on 1 July 2014 [5]. The statistical anal-
yses were conducted in Stata version 14. We used the χ2
statistic to test association between implementation of
measures and countries’ income level. We used the
McNemar exact test to assess changes in implementation
between our two surveys.
RESULTS
Survey response rate
We received responses from contacts in 142 countries, an
83% response rate. Response rates by income level were:
92% in high-income countries (HIC, n= 49), 80% in upper
middle-income countries (UMIC, n = 40), 82% in lower
middle-income countries (LMIC, n = 36) and 68% in low-
income countries (LIC, n = 17).
Basic treatment infrastructure
According to respondents, just more than half of countries
had a government ofﬁcial responsible for treatment (54%).
Only a quarter reported having a clearly identiﬁed treat-
ment budget (25%), fewer than a third an ofﬁcial treat-
ment strategy (32%) and fewer than half ofﬁcial national
treatment guidelines (40%). Just under a third reported
mandatory recording of tobacco use in medical notes
(30%) and fewer than half that cessation support was
offered to HCW to stop using tobacco (44%) (Table 1). Just
more than 80% reported training some HCW to give brief
advice andmore than a third incorporated tobacco cessation
into training curricula of health-care students and workers
(36%). There was a signiﬁcant difference in provision across
income level for treatment budget, ofﬁcial treatment strat-
egy, national treatment guidelines and cessation in training
curricula, but not for the other measures (Table 1).
Cessation support systems
Mass media campaigns
Overall, only 13% of respondents reported mass media
campaigns promoting cessation in the past 6 months:
23% of HIC, 15% of UMIC, 3% of LMIC and 6% of LIC
(P = 0.002 for difference across income level, Table 2).
Brief advice
According to respondents, brief advice was integrated into
existing services in fewer than half of countries (44%):
51% of HIC, 48% of UMIC, 31% of LMIC and 41% of LIC
(P = 0.281 for difference across income level, Table 2).
Text messaging
Overall, 17% of respondents reported that text messaging
support was available in their countries: 35% of HIC, 8%
of UMIC, 11% of LMIC and no LIC (P< 0.001 for difference
across income level, Table 2).
Quitlines
Free quitlines with national coverage were reported by
23% of respondents overall: 53% of HIC, 15% of UMIC,
3% of LMIC and no LIC (P< 0.001 for difference across in-
come level, Table 2). Quitlines in selected regions, or
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helplines that were not tobacco-only, were reported in
fewer than 10% of countries.
More than 80% of respondents reported that all
quitlines had people answering always or almost always,
and referred callers to local treatment services. Just more
than half offered multiple sessions with counsellors calling
back, and 67% provided information about tobacco
cessation medications (Table 2).
Specialized treatment support
Respondents in just more than a quarter of countries
(26%) reported a network of specialized tobacco
Table 1 Tobacco treatment infrastructure by World Bank income level.
Question, % Yes (n) All (142) HIC (49) UMIC (40) LMIC (36) LIC (17)
P-value for
difference across
income level
Is there an ofﬁcially identiﬁed person in government (or
contracted by government) who is responsible for tobacco
dependence treatment?
54 (76) 57 (28) 63 (25) 53 (19) 24 (4) 0.052
Does your country have a clearly identiﬁed budget for tobacco
dependence treatment?
25 (35) 43 (21) 20 (8) 17 (6) 0 (0) 0.001
Does your country have an ofﬁcial, written, national tobacco
treatment strategy?
32 (46) 51 (25) 25 (10) 31 (11) 0 (0) < 0.001
Does your country have ofﬁcial national tobacco treatment
guidelines?
40 (57) 63 (31) 38 (15) 28 (10) 6 (1) < 0.001
Is it mandatory to record patients’ tobacco use in medical
notes in your country?
30 (42) 39 (19) 25 (10) 25 (9) 24 (4) 0.425
Does your country offer help to health-care workers and
other relevant groups to stop using tobacco?
44 (63) 53 (26) 53 (21) 25 (9) 41 (7) 0.132
Are health-care workers trained to give brief advice?
(Yes, some)
81 (100) 73 (36) 80 (32) 58 (21) 65 (11) 0.129
Is tobacco cessation incorporated into the training curricula
of health-care students and workers?
36 (51) 59 (29) 28 (11) 19 (7) 24 (4) < 0.001
HIC = high-income countries; UMIC = upper middle-income countries; LMIC = lower middle-income countries; LIC = low-income countries. Bold data
indicate percentages.
Table 2 Tobacco cessation support systems by World Bank income level.
Question, % Yes (n) All (142) HIC (49) UMIC (40) LMIC (36) LIC (17)
P-value for
difference across
income level
Mass media campaigns promoting cessation in the
past 6 months?
13 (19) 23 (11) 15 (6) 3 (1) 6 (1) 0.002
Brief advice integrated into existing services? 44 (62) 51 (25) 48 (19) 31 (11) 41 (7) 0.281
Cessation support via text messaging? 17 (24) 35 (17) 8 (3) 11 (4) 0 (0) 0.001
Quitlines
A free national quitline in all major regions? 23 (33) 53 (26) 15 (6) 3 (1) 0 (0) < 0.001
A free quitline but only in selected regions? 6 (9) 4 (2) 10 (4) 8 (3) 0 (0)
A free national quitline but not tobacco only? 8 (11) 10 (5) 8 (3) 6 (2) 6 (1)
People answering always or almost always? 82 (42) 87 (27) 85 (11) 50 (3) 100 (1)
Offer multiple sessions with counsellors calling back
to offer support?
51 (26) 66 (20) 39 (5) 17 (1) 0 (0)
Refer callers to local specialist treatment services? 84 (43) 87 (27) 92 (12) 50 (3) 100 (1)
Offer information about tobacco cessation medications? 67 (34) 74 (23) 62 (8) 33 (2) 100 (1)
Specialized tobacco dependence treatment service
A network of support covering the whole country? 26 (37) 55 (27) 20 (8) 6 (2) 0 (0) < 0.001
Treatment support in selected areas? 37 (53) 35 (17) 45 (18) 33 (12) 35 (6)
Free to users? 48 (43) 55 (24) 54 (14) 14 (2) 50 (3)
Partially free to users? 38 (35) 36 (16) 31 (8) 57 (8) 50 (3)
Not free to users? 12 (11) 7 (3) 15 (4) 29 (4) 0 (0)
HIC = high-income countries; UMIC = upper middle-income countries; LMIC = lower middle-income countries; LIC = low-income countries. Bold data
indicate percentages.
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dependence treatment services covering the whole coun-
try: 55% of HIC, 20% of UMIC, 6% of LMIC and no LIC
(P < 0.001 for difference across income level, Table 2).
An additional third (37%) reported specialized treat-
ment support in selected areas: 35% of HIC, 45% of UMIC,
33% of LMIC and 35% of LIC.
Specialized treatment support was free to users in 48%
of countries that offered it: 55% of HIC, 54% of UMIC, 14%
of LMIC and 50% of LIC (Table 2).
Access to cessation support
Respondents in more than half of countries reported that
tobacco users could access cessation support from general
practitioners (GPs) (67%), hospitals (62%), addiction ser-
vices (59%) and pharmacies (51%) and in 49% of mental
health settings. Cessation support from dentists, educa-
tional institutions, work-places and prisons could be
accessed in fewer than a third of countries. Access to cessa-
tion support from GPs, pharmacies, dentists, addiction
services, work-places and prisons was signiﬁcantly less in
middle- and low-income countries than in high-income
countries (Fig. 1).
Availability of cessation medications
In approximately three-quarters of countries, respon-
dents reported that nicotine patches and gum were
available, ranging from 98% of HIC to 47% of LIC
(P < 0.001 for difference across income level). Avail-
ability of bupropion and varenicline also decreased with
income level. Bupropion was reported to be available in
90% of HIC and 18% of LIC (P < 0.001 for difference
across income level), varenicline in 88% of HIC and
6% of LIC (P < 0.001 for difference across income
level, (Table 3). Cytisine was reported to be available
only in 14% of countries overall (P = 0.692 for differ-
ence across income level).
Affordability of cessation medications
In countries where cessation medications were available,
most respondents rated them as affordable, but with a
clear gradient from high- to low-income countries. For
example, nicotine gum was rated affordable in 85% of
HIC, 58% of UMIC, 45 of LMIC and 33% of LIC
(P < 0.001 for difference across income level);
varenicline was rated affordable in fewer than a third
of UMIC and LMIC and in no LIC. There was no income
gradient in the affordability of cytisine (P = 0.821)
(Table 4).
Changes in treatment provision since 2012
We compared our current results with our previous survey
in 2012, for those measures which were comparable, for a
subset of 99 countries that completed both surveys and did
not change their WB income level: 36 HIC, 28 UMIC, 23
LMIC and 12 LIC (Table 5).
Overall, while provision of some measures reportedly
increased over time, such as having a government ofﬁcial
responsible for cessation, an increase of 13 percentage
points (P = 0.0351) and treatment guidelines, an increase
of 9 percentage points (P = 0.629), there was little change
in others, such as mass media campaigns promoting
cessation, mandatory recording of tobacco use in medical
notes, an ofﬁcial treatment budget and having a free
national quitline (Table 6).
Figure 1 Access to cessation support in different settings. ‘Can tobacco users get help to stop smoking in the following settings?’. The bars show
‘Yes’ responses overall (black) then by income-level in the order high-income countries (HIC); upper middle-income countries (UMIC); lower
middle-income countries (LMIC); low-income countries (LIC). P-values are for difference across income level
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DISCUSSION
Our main ﬁnding is that implementation of FCTC Article
14 remains slow, with relatively little improvement during
the last 3 years. Overall, in 2015, only three measures in
our survey were reported to be in place in the majority of
countries: 81% reported training some HCW to give brief
advice, just more than half (54%) a nominated ofﬁcial
responsible for tobacco dependence treatment and just
more than 50% providing access to cessation support in
primary care, pharmacies and hospitals. All other infra-
structure and support systems were provided in only a mi-
nority of countries. Only 25% reported having an identiﬁed
treatment budget, fewer than a third had an ofﬁcial treat-
ment strategy (32%), fewer than half had ofﬁcial treatment
guidelines (40%), only 30%mandated recordingof tobacco
Table 3 Availability of cessation medications by World Bank income level.
Medication
Available, % Yes (n)
P-value for difference
across income levelAll (142) HIC 49) UMIC (40) LMIC (36) LIC (17)
NRT patch 74 (104) 98 (48) 73 (29) 53 (19) 47 (8) <0.001
NRT gum 72 (102) 96 (47) 60 (24) 61 (22) 53 (9) < 0.001
Other NRT 45 (63) 69 (34) 40 (16) 25 (9) 24 (4) < 0.001
Bupropion 60 (84) 90 (44) 58 (23) 39 (14) 18 (3) < 0.001
Varenicline 54 (76) 88 (43) 48 (19) 36 (13) 6 (1) < 0.001
Nortriptyline 33 (46) 53 (26) 28 (11) 19 (7) 12 (2) 0.001
Cytisine 14 (19) 10 (5) 13 (5) 19 (7) 12 (2) 0.692
HIC = high-income countries; UMIC = upper middle-income countries; LMIC = lower middle-income countries; LIC = low-income countries; NRT = nicotine
replacement therapy.
Table 4 Affordability of cessation medications by World Bank income level.
Medication
Affordable, % Yes (n)
P-value for difference
across income levelAll HIC UMIC LMIC LIC
NRT patch 63 (65) 79 (36) 52 (15) 53 (10) 25 (2) < 0.001
NRT gum 66 (67) 85 (40) 58 (14) 45 (10) 33 (3) < 0.001
Other NRT 68 (43) 94 (32) 38 (6) 44 (4) 25 (1) < 0.001
Bupropion 57 (48) 73 (32) 43 (10) 36 (5) 33 (1) < 0.001
Varenicline 54 (41) 77 (33) 32 (6) 15 (2) 0 (0) < 0.001
Nortriptyline 59 (27) 65 (17) 55 (6) 57 (4) 0 (0) 0.003
Cytisine 68 (13) 80 (4) 80 (4) 57 (4) 50 (1) 0.821
The percentages are calculated by dividing the number of countries where the medication is affordable by the number of countries where the medication
is available (n), as shown in Table 3. HIC = high-income countries; UMIC = upper middle-income countries; LMIC = lower middle-income countries;
LIC = low-income countries; NRT = nicotine replacement therapy.
Table 5 Country respondents in 2012 and 2015 by income.
Countries WB
income category
Responded in 2012
survey, n
Responded in 2015
survey, n
Excluded from longitudinal
analyses (did not respond or
changed income category), n
Included in
longitudinal
analyses, n
Low-income 19 17 5 12
Lower middle-income 30 36 13 23
Upper middle-income 36 40 12 28
High-income 36 49 13 36
All 121 142 43a 99
aThe 43 excluded countries included 23 that did not respond in the 2012 survey, 12 that did not respond in the 2015 survey and 10 that changed theirWorld
Bank (WB) income category.
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use in medical notes, and there continued to be a clear
income gradient in provision. For most measures, andwith
few exceptions, treatment provision was available in more
high- than middle- and low-income countries.
To our knowledge, this is themost detailed and compre-
hensive tobacco treatment survey conducted to date, sent
to contacts in 94% of FCTC Parties at the time of the survey
and achieving an 83% response rate. However, a survey of
such scale has limitations. We used a purposive sample of
contacts with expertise in tobacco cessation or tobacco
control identiﬁed through various channels, some from
national government, others outside government; hence,
there is potential response bias and subjectivity in some
responses. To minimize response bias, we encouraged the
respondents to discuss and verify their responses with
colleagues and, where possible, provide supporting infor-
mation with their answers, such as copies of documents
and links to websites. Wherever possible, we corroborated
the responses using data from our previous survey or other
sources. Differences in cultural context and respondents’
expertise could lead occasionally to differences in interpre-
tations of questions about national cessation strategy and
guidelines, or mass media campaigns. In particular,
respondents may not distinguish between occasional
advertisements on television and a major, comprehensive
mass media campaign. When necessary, we corresponded
with the respondents to check and clarify their answers.
Our main ﬁnding, that progress in Article 14
implementation is slow, is consistent with that of the
2014 WHO Global Progress Report [6]. Based on 130
Parties’ implementation reports, the report estimated that
the average implementation rate of the provisions under
Article 14 was 51%, below that of other substantive
articles: 84% for Article 8 (Protection from exposure to to-
bacco smoke); 70% for Article 11 (Packaging and labelling
of tobacco products); 63% for Article 13 (Tobacco
advertising, promotion and sponsorship); and 62% for
Article 6 (Price and tax measures to reduce the demand
for tobacco) [6].
As with the previous survey, we found a positive rela-
tionship between income level and treatment [4]. This is
not surprising, as many HIC had already had treatment
infrastructure in place [7–9] prior to the FCTC entry into
force in 2005, while for many middle- and low-income
countries, engagement with tobacco treatment might
not have started before the adoption of the Article 14
implementation guidelines in 2010 [3]. If this trend in
tobacco treatment provision across countries’ income
level continues, it will lead inevitably to widening health
inequality between HIC and middle- and low-income
countries.
The clear income gradient in almost all our main mea-
sures suggests that cost is (or is perceived to be) a barrier
to the implementation of Article 14, with just a quarter of
countries in the whole sample, and no LIC, having a
clearly identiﬁed budget for tobacco dependence
treatment. The Article 14 guidelines emphasize the
importance of securing sustainable funding for cessation
through tobacco price and tax increases, but clearly few
countries have done so yet, although some countries (for
example Panama, Korea) have identiﬁed adequate
funding for treatment.
However, the Article 14 guidelines also stress the
importance of using existing infrastructure and resources
as much as possible, in order to keep costs down and
facilitate quick action, and highlight several measures that
are low cost. These include identifying tobacco users in
medical notes and integrating brief advice by an HCW into
the existing health-care system, as well as developing an
ofﬁcial national strategy and guidelines.
Recording tobacco use in all medical notes is essential
to identify tobacco users and thus put the issue onto the
health-care system agenda, as well as providing an oppor-
tunity for brief advice to stop smoking. Brief advice given
by a primary care physician has been shown to encourage
quit attempts and can potentially be one of the most cost-
effective interventions when implemented throughout the
health-care system [7]. According to a survey of smokers
Table 6 Changes in treatment provision from 2012 to 2015.
Question 2012 % Yes (n) 2015 % Yes (n) Change P- value for change
Government ofﬁcial responsible for cessation? 40 (40) 54 (53) 13 0.035
Treatment budget? 22 (22) 23 (23) 1 1.00
Treatment guidelines? 46 (46) 56 (55) 9 0.629
Mandatory recording tobacco use in patients’ notes? 21 (21) 26 (26) 5 0.774
Health-care workers offered help to stop using tobacco? 46 (46) 42 (42) –4 0.487
Mass media campaigns promoting cessation? 55 (54) 56 (55) 1 1.00
National free quitline? 29 (29) 30 (30) 1 1.00
Specialized cessation services covering the whole country or
in selected areas?
69 (68) 69 (68) 0 1.00
The total base is 99—the number of countries who completed the survey in 2012 and 2015. The change is in percentage points. Bold data indicate
percentages.
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in 15 countries, between 50 and 70% of smokers visited a
physician or other health-care providers during 1 year
[10]. Our ﬁnding, that only 30% of countries record
tobacco use in medical notes and only 44% provide brief
advice as part of the existing health-care services,
demonstrates the potential for quick improvement in the
provision of low-cost broad-reach interventions that would
save many lives.
Delivering anti-smoking messages and encouraging
quit attempts via mass communication channels are
measures recommended by both Article 14 and Article
12 guidelines [3,11]. Mass media campaigns in particular
can potentially have wide population reach and low
per-capita cost [12]. However, such campaigns require
substantial funding and may not be easily affordable in
middle- and low-income countries. Our ﬁndings showed
that just more than half of respondents reported that their
countries ran mass media campaigns promoting
cessation, and this increased by only one percentage point
during the last 3 years. Effective mass media campaigns
[13] can be adapted for use with smokers in different
countries, thus reducing the set-up and production cost
substantially. Self-help materials (leaﬂets, booklets),
printed or distributed electronically, is another affordable
measure [14] that can be effective in lower-income coun-
tries with widespread literacy and internet access. How-
ever, evidence suggests that adequately funded mass
media campaigns need to be sustained over a period of
time to be optimally effective as part of a comprehensive
tobacco control strategy [15,16].
We found that free national quitlines were available
in only 23% of countries (Table 2), and increased by just
one percentage point during the last 3 years in our
cohort of 99 countries (Table 5). Quitlines require invest-
ment in infrastructure, people and training. As demand
for cessation continues to grow in middle- and low-
income countries [17,18], text messaging might be a
cheaper alternative to quitlines. There is emerging
evidence of the effectiveness of behavioural support
delivered via automated mobile phone text messaging
[14].
Although medicines availability is excellent in HIC (for
example almost all HIC have NRT; Table 3), the availabil-
ity of affordable cessation medications remains an issue
for middle- and low-income countries, including those
medications considered to be globally affordable by a
WHO deﬁnition [14]. We found that nicotine replacement
therapy (NRT) patches and gum, which have been on the
WHO List of Essential Medications since 2009 [19,20],
are available in just more than half of LMIC and
approximately half of LIC, and their affordability is low.
Cytisine, a low-cost medication, estimated to be 25 times
cheaper than varenicline [21], is not licensed as a cessa-
tion medication outside countries in Central and Eastern
Europe, and was available in fewer than 20% of middle-
and low-income countries.
Cessation medications have been shown to increase the
success rate of cessation attempts [22,23]. The Article 14
guidelines recommend that countries should make
cessation medications available for tobacco users wanting
to quit, and where possible provide them free or at an
affordable cost. As cigarettes are becoming more affordable
over time in middle- and low-income countries [24],
countries need to implement measures to reduce the cost
of NRT and license low-cost cessation medications such
as cytisine, estimated to be a globally affordable
intervention [14] .
Our cohort data showed very little change in specialized
treatment services. Although all countries should aim
eventually for comprehensive treatment provision, free
nation-wide specialized cessation services such as those
in England clearly require a national cessation strategy
and government funding [25], and thus are unlikely to be
feasible in middle- and low-income countries. An addi-
tional consideration here is coverage, as they tend to reach
a small proportion of the population.Were such specialized
support to be delivered by trained multiple providers, in-
cluding GPs, nurses, dentists, pharmacists and community
workers, as well as cessation specialists, and also delivered
through telephone counselling [26,27], then they might
achieve better reach. However, we believe middle- and
low-income countries should follow the Article 14 guide-
lines by ﬁrst prioritizing core infrastructure broad-reach
low-cost measures.
The main recommendations of Article 14 and its
guidelines were that countries should develop and
disseminate national treatment guidelines and a national
cessation strategy, yet this has been achieved by only
40% of countries, an increase of only 9 percentage points
in the last 3 years.
FCTC A14 implementation is slow and shows a signiﬁ-
cant gradient by income level, with less treatment provi-
sion the lower the income. If the current pattern of
implementation continues the gap between HIC and
middle- and low-income countries will grow wider, wors-
ening existing health inequalities between countries. Im-
plementation needs to be improved, with an emphasis on
affordable, broad-reach measures. This means prioritizing
core infrastructure measures, including developing an ofﬁ-
cial national cessation strategy and guidelines, mandatory
recording of tobacco use in medical notes and helping
HCW to stop using tobacco, along with broad-reach
low-cost interventions, including brief advice and text
messaging.
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